Surveillance for hepatocellular carcinoma: Can we focus on the mission?

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 805-807

  Kanwal, Fasiha ^a   El Serag, Hashem B ^a   Ross, David ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; PLACEBO;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DECISION SUPPORT SYSTEM; DRINKING BEHAVIOR; ECHOGRAPHY; EDITORIAL; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GASTROENTEROLOGIST; GENERAL PRACTITIONER; HEALTH INSURANCE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIMARY PREVENTION; SCREENING TEST; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; VACCINATION; CARCINOMA, HEPATOCELLULAR; CLINICAL PRACTICE; EARLY DIAGNOSIS; FEMALE; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; LIVER NEOPLASMS; MALE; PRIMARY HEALTH CARE; PROCEDURES;

ATTITUDE OF HEALTH PERSONNEL; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIVER NEOPLASMS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE;

EID: 84924940693     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.12.016     Document Type: Editorial

References (25)

1. El-Serag H.B. Hepatocellular carcinoma. NEngl J Med 2011, 365:1118-1127.
2. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148. HALT-C Trial Group.
3. Yang J.D., Kim W.R., Coelho R., et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:64-70.
4. Artinyan A., Mailey B., Sanchez-Luege N., et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010, 116:1367-1377.
5. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. NEngl J Med 1997, 336:1855-1859.
6. Wasley A., Grytdal S., Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008, 57:1-24. Centers for Disease Control and Prevention (CDC).
7. Bichoupan K., Martel-Laferriere V., Sachs D., et al. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 2014, 60:1187-1195.
8. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
9. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. JHepatol 2010, 53:348-356.
10. Gordon S.C., Lamerato L.E., Rupp L.B., et al. Antiviral therapy for chronic HBV infection and development of hepatocellular carcinoma in a U.S. population. Clin Gastroenterol Hepatol 2014, 12:885-893. CHeCS Investigators.
11. Zoutendijk R., Reijnders J.G., Zoulim F., et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013, 62:760-765. VIRGIL Surveillance Study Group.
12. Morgan R.L., Baack B., Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158:329-337.
13. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
14. Sherman M., Bruix J., Porayko M., et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases Recommendations. Hepatology 2012, 56:793-796. AASLD Practice Guidelines Committee.
15. Singal A.G., Li X., Tiro J., et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015, 128:90.e1-90.e7.
16. Dalton-Fitzgerald E., Tiro J., Kandunoori P., et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015, 13:791-798.
17. McGowan C.E., Edwards T.P., Luong M.U., et al. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 2015, 13:799-804.
18. Kanwal F., Volk M., Singal A., et al. Improving quality of healthcare for patients with cirrhosis. Gastroenterology 2014, 147:1204-1207.
19. Wang Y., Luo Q., Li Y., Deng S., Wei S., Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014, 9:e84484.
20. Cammà C., Schepis F., Orlando A., et al. Transarterial hemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54.
21. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359:378-390. SHARP Investigators Study Group.
22. Beste L.A., Ioannou G.N., Yang Y., et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 2015, 13:172-179.
23. Blumenthal D., Tavenner M. The "meaningful use" regulation for electronic health records. NEngl J Med 2010, 363:501-504.
24. Poustchi H., Farrell G.C., Strasser S.I., et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 2011, 54:1998-2004.
25. Kansagara D., Papak J., Pasha A.S., et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014, 161:261-269.